Literature DB >> 11168089

Clinico-diagnostic experience with tuberculous lymphadenitis in Saudi Arabia.

Z A Memish1, M W Mah, S A Mahmood, R M Bannatyne, M Y Khan.   

Abstract

OBJECTIVES: To describe the diagnosis and outcomes of tuberculous lymphadenitis in a low HIV-seroprevalence population at a hospital in Riyadh, Saudi Arabia.
METHODS: Retrospective case series of tuberculous lymphadenitis from 1983 to 1998 were examined.
RESULTS: There were 99 cases with a median age of 38 years and a female preponderance (female/male ratio of 1.3 : 1). Eighty per cent had cervical involvement and 36% had systemic symptoms. Eighty-nine per cent had their lymphadenopathy for more than 1 month. The diagnostic yield of tuberculin skin testing was 83%, of chest X-ray was 27%, of fine-needle aspiration was 46%, and of excisional lymph node biopsy was 97%. Only one-third of patients received a tuberculin test. There was no significant difference in outcome between 6 and 9 months of chemotherapy, and paradoxical enlargement of nodes occurred in only 6%.
CONCLUSIONS: Tuberculous lymphadenitis in our study population was predominantly cervical in location. The diagnostic yield of FNA was lower than that reported in the literature, and might be improved by more frequent tuberculin skin testing, multiple aspirations of lymph nodes, or use of excisional biopsy as the initial diagnostic procedure. Most patients responded well to chemotherapy, with few complications.

Entities:  

Mesh:

Year:  2000        PMID: 11168089     DOI: 10.1046/j.1469-0691.2000.00033.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  9 in total

1.  Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients.

Authors:  V C C Cheng; W C Yam; P C Y Woo; S K P Lau; I F N Hung; S P Y Wong; W C Cheung; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-09-24       Impact factor: 3.267

2.  A Case of Obstructive Jaundice Caused by Paradoxical Reaction during Antituberculous Chemotherapy for Abdominal Tuberculosis.

Authors:  Yun Jung Lee; Sung Hee Jung; Woo Jin Hyun; Sae Hee Kim; Hyang Ie Lee; Hyeon Woong Yang; Anna Kim; Sang Woo Cha
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

3.  The causes of lymphadenopathy in the central region of Saudi Arabia: a clinicopathological analysis of 475 cases.

Authors:  Khadega A Abuelgasim; Neam H Salih; Saud M Al Jesh; Mohammad O Al-Kaiyat; Saeed S Alshieban
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

4.  Outcomes of category III and I in immunocompetent patients of tuberculous lymphadenopathy treated in revised national tuberculosis control programme.

Authors:  Nageen Kumar Jain; Ashok Bajpai; Shikha Jain
Journal:  Lung India       Date:  2010-07

5.  Paradoxical upgrading reaction in extra-pulmonary tuberculosis: association with vitamin D therapy.

Authors:  D A Barr; A K Coussens; S Irvine; N D Ritchie; K Herbert; B Choo-Kang; D Raeside; D J Bell; R A Seaton
Journal:  Int J Tuberc Lung Dis       Date:  2017-06-01       Impact factor: 2.373

6.  Loss of vision and hearing in a case of cervical lymph node tuberculosis: A rare paradoxical reaction.

Authors:  Swapnil Manaji Thorve; Neelakanth S Patil; Saurabh Mandilwar; Agam Vora
Journal:  Lung India       Date:  2017 Nov-Dec

7.  Left Lateral Cervical Mass with Draining Sinuses.

Authors:  Stylianos A Michaelides; George D Bablekos; Avgerinos-Romanos Michailidis; Efthalia Gkioxari; Stephanie Vgenopoulou; Maria Chorti
Journal:  Case Rep Med       Date:  2019-07-25

8.  A case of paradoxical reaction after treatment of generalized tuberculous lymphadenopathy in a peritoneal dialysis patient.

Authors:  Farah Gul Khan; Stanley Fan
Journal:  SAGE Open Med Case Rep       Date:  2022-03-15

9.  Acute respiratory distress during paradoxical reaction to antituberculous therapy in an 8-month-old child.

Authors:  Ira Shah; Sujeet Chilkar; Manisha Patil; Uma Ali
Journal:  Lung India       Date:  2012-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.